REG - ValiRx PLC - Shareholder Communications

ValiRxAnnouncement

17/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220817:nRSQ2408Wa&default-theme=true

RNS Number : 2408W  ValiRx PLC  17 August 2022

17 August 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Shareholder Communications

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to announce the
appointment of strategic marketing and PR agency, V Formation Limited and the
appointment of Dr Adam Hargreaves as a shareholder representative. The
appointments represent the Company's continued strategy to improve and enhance
communications with its shareholders.

V Formation Limited is a Nottingham-based public relations and marketing
communications agency that specialises in supporting clients in the life
sciences sector, ensuring that news and corporate development updates are
optimised and communicated in a clear, transparent and precise manner.  V
Formation will liaise closely with Dr Hargreaves in his role as shareholder
representative, as well as with ValiRx's Nominated Adviser and brokers, to
improve the interpretation and dissemination of Company newsflow following
publication via a regulatory information provider.

Dr Adam Hargreaves has agreed to become a shareholder representative to help
improve communications between the Company and shareholders.  The Company's
overall policy on shareholder communications is unchanged, with written
quarterly updates and quarterly live Q&A events continuing.  However,
shareholders can additionally communicate with Dr Hargreaves directly to seek
clarification of any details that have been publicly announced, or through a
shareholder community.  Dr Hargreaves will have regular interaction with the
Company to ensure that shareholders' views are fully represented to the
Board.  Shareholders wishing to communicate directly with Board members are
welcome to do so, with a prompt response when possible.

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Dr Adam Hargreaves, Shareholder Representative      Adam.Hargreaves@pathcelerate.com (mailto:Adam.Hargreaves@pathcelerate.com)

 V Formation (Public Relations)

                                                     Contact details

 Lucy Wharton - Senior PR Executive                  www.vformation.biz (http://www.vformation.biz)

 Sue Carr - Director                                 lucy@vformation.biz (mailto:lucy@vformation.biz)

                                                     sue@vformation.biz (mailto:sue@vformation.biz)

                                                     +44 (0)115 787 0206
 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 088

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities Limited (Joint Broker)            Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

About V Formation

V Formation is an established marketing and PR agency based at BioCity
Nottingham. The team of experienced marketing and PR consultants deliver
inspiring, insightful and supportive marketing advice, strategy and tactics to
take businesses closer to their clients and help them find their competitive
edge.

 

V Formation works with ambitious SMEs in the life sciences and high-tech
sectors, professional services firms and family businesses. It provides
in-house marketing and support, guidance on strategic direction and assistance
with tactical marketing and PR. The company's directors are Sue Carr and
Hilary Campton.

 

For more information: www.vformation.biz (http://www.vformation.biz/) or 0115
822 6364

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDIISBDGDL